ArticleEuropean archives of psychiatry and clinical neuroscience2026
The discontinuation-emergent signs and symptoms (DESS) scale: reliable measurement-but perhaps not of antidepressant withdrawal.
Article in European archives of psychiatry and clinical neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMost patients discontinuing antidepressants (ADs) report withdrawal symptoms. The Discontinuation-Emergent Signs and Symptoms (DESS) checklist is widely used to assess such symptoms, although concerns about its validity remain.
methodsThis naturalistic study investigated the reliability and construct validity of a self-report version of the DESS in an inpatient sample with major depressive disorder (N = 63). Thirty-three patients discontinued a previously prescribed AD (disAD group), whereas 30 patients received no AD during treatment (noAD group). The DESS and the revised Beck Depression Inventory-II were administered. Three time points were analyzed: baseline (T0), defined as the day before the first dose reduction in the disAD group, and the first two assessments following complete discontinuation (T1, T2). Reference time points in the noAD group were yoked to the assessment schedule of the disAD group.
resultsInternal consistency of the DESS ranged from good to excellent. In the disAD group, correlations between DESS and depression scores were weak and non-significant, whereas strong correlations were observed in the noAD group. ANCOVA indicated that DESS scores did not differ between groups but decreased significantly over time. Notably, the highest DESS scores were observed at T0, prior to AD discontinuation. Item-level analyses provided no evidence that individual items captured withdrawal symptoms.
conclusionsAlthough reliable, the self-report DESS showed limited construct validity as a measure of AD withdrawal symptoms. Instead, the instrument may primarily capture depressive symptoms or AD-related adverse effects.
Indexed as
Identifiers
42814111What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.